Clinical Trial Update: An Open Label, Dose Titration Study of Sevelamer Carbonate Tablets & Powder in Hyperphosphatemic CKD Patients [Phase 3]

View source ↗

Summary

A Phase 3 open-label, dose-titration study of sevelamer carbonate tablets and powder for hyperphosphatemia in chronic kidney disease, which has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• SEVELAMER CARBONATE (sevelamer carbonate)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Renal Failure Chronic | Phase 3 | Status: COMPLETED